|
1）岡崎 聡，杉原健一．疫学的知見から大腸がん治療への将来展望．日本臨牀．2014; 72: 9-14
|
|
|
|
2）Ishikawa H, Mutoh M, Suzuki S, et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in asian patients: A randomised trial. Gut. 2014; 63: 1755-9
|
|
|
|
|
3）Dovizio M, Tacconelli S, Sostres C, et al. Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals (Basel). 2012; 5: 1346-71
|
|
|
|
|
|
4）Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the melbourne colorectal cancer study. Cancer Res. 1988; 48: 4399-404
|
|
|
|
|
|
5）Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991; 325: 1593-6
|
|
|
|
|
|
6）Jacobs EJ, Thun MJ, Bain EB, et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007; 99: 608-15
|
|
|
|
|
|
7）Chan AT, Giovannucci EL, Meyerhardt JA, et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology. 2008; 134: 21-8
|
|
|
|
|
|
8）Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005; 294: 914-23
|
|
|
|
|
|
9）Ruder EH, Laiyemo AO, Graubard BI, et al. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol. 2011; 106: 1340-50
|
|
|
|
|
|
10）Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet. 2007; 369: 1603-13
|
|
|
|
|
|
11）Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012; 13: 518-27
|
|
|
|
|
|
12）Gann PH, Manson JE, Glynn RJ, et al. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993; 85: 1220-4
|
|
|
|
|
|
13）Sturmer T, Glynn RJ, Lee IM, et al. Aspirin use and colorectal cancer: Post-trial follow-up data from the physiciansʼ health study. Ann Intern Med. 1998; 128: 713-20
|
|
|
|
|
|
14）Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: The womenʼs health study: A randomized controlled trial. JAMA. 2005; 294: 47-55
|
|
|
|
|
|
15）Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010; 376: 1741-50
|
|
|
|
|
|
16）Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet. 2011; 377: 31-41
|
|
|
|
|
|
17）Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012; 379: 1602-12
|
|
|
|
|
|
18）Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: Meta-analysis of the randomized trials. J Natl Cancer Inst. 2009; 101: 256-66
|
|
|
|
|
|
19）Burn J, Bishop DT, Chapman PD, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila). 2011; 4: 655-65
|
|
|
|
|
|
20）Ishikawa H, Wakabayashi K, Suzuki S, et al. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: Double-blind, randomized clinical trial. Cancer Med. 2013; 2: 50-6
|
|
|
|
|
|
21）Burn J, Bishop DT, Mecklin JP, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the lynch syndrome. N Engl J Med. 2008; 359: 2567-78
|
|
|
|
|
|
22）Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the capp2 randomised controlled trial. Lancet. 2011; 378: 2081-7
|
|
|
|
|